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Abstract
Background: Alveologenesis is the last stage in lung development and is essential for building the gas-exchanging
units called alveoli. Despite intensive lung research, the intricate crosstalk between mesenchymal and epithelial cell
lineages during alveologenesis is poorly understood. This crosstalk contributes to the formation of the secondary
septae, which are key structures of healthy alveoli.
Conclusions: A better understanding of the cellular and molecular processes underlying the formation of the
secondary septae is critical for the development of new therapies to protect or regenerate the alveoli. This review
summarizes briefly the alveologenesis process in mouse and human. Further, it discusses the current knowledge on
the epithelial and mesenchymal progenitor cells during early lung development giving rise to the key cellular
players (e.g., alveolar epithelial cell type I, alveolar epithelial cell type II, alveolar myofibroblast, lipofibroblast)
involved in alveologenesis. This review focusses mainly on the role of fibroblast growth factor 10 (FGF10), one of
the most important signaling molecules during lung development, in epithelial and mesenchymal cell lineage
formation.
Keywords: Alveologenesis, Fibroblast growth factor 10 (FGF10), Alveolar epithelial cell type I (AEC I), Alveolar
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Introduction
Mouse and human lung development consists of four
histologically distinguishable stages termed pseudoglandu-
lar (mouse, E9.5–E16.5; human, weeks 4–17), canalicular
(mouse, E16.5–E17.5; human, weeks 17–26), saccular
(mouse, E17.5–P5; human, weeks 26–36), and alveolar
(mouse, P5–P30; human, weeks 36–8 years) stages. Dur-
ing the pseudoglandular stage, branching morphogenesis
occurs to form the tree-like tubular structure of the lung,
which later becomes the conducting airway. At the same
time, several mesenchymal and epithelial progenitor cells
differentiate into smooth muscle cells, lymphatic cells,
endothelial cells, nerve cells, and chondrocytes, as well
as basal cells, neuroendocrine cells, ciliated cells, and
secretory cells, respectively. Apart from the further
branching process of the respiratory bronchioles, one
of the main events during the canalicular stage is the
formation of a double-layer capillary network. Further-
more, alveolar bipotential progenitor cells give rise to
alveolar epithelial cells type I (AEC I) and type II (AEC II)
[1], leading to the first primitive respiratory epithelium
capable of gas exchange. Another important cell type
emerging in canalicular stage is the so-called lipofibroblast
(LIF), which is involved in surfactant production through
interaction with the AEC II and constitute a potential
stem cell niche for AEC II stem cells. The following saccu-
lar stage (E17.5-P5) is characterized by alveolar sac forma-
tion (primitive alveoli), surfactant production, and the
ongoing expansion of the capillary and lymphatic net-
works (Fig. 1a, b). Through thinning of the mesenchyme
due to apoptosis of mesenchymal cells [2], the distance be-
tween the blood vessels located in the mesenchyme and
the alveolar epithelial surface decreases, thus facilitating
oxygen diffusion. Finally, the last stage of lung maturation
is the alveolar stage (P5–P30). The lung undergoes a dras-
tic increase in alveolar surface area by subdividing the al-
veolar sac through a process called the secondary septae
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formation. This produces the mature respiratory units
called alveoli (Fig. 1c). An adult mouse lung consists of
about 2.3 Mio. alveoli (alveolar surface area, 82 cm2) [3]
and in an adult human lung about 300 Mio. alveoli (alveo-
lar surface area, 75 m2) [4]. The number of lung lobes and
airway generations is also different between a mouse and a
human. While the mouse lung is comprised of four lobes
on the right side and one lobe on the left side, the human
lung develops three lobes on the right and two on the left.
The mouse bronchial tree consists of 12 airway genera-
tions compared to 23 in the human lung. Last but not
least, the probably most interesting difference between
mouse and human lung development is that the mouse
is born during the saccular stage and the human during
the alveolar stage of lung development. Therefore, the
hyperoxia-induced lung injury model in the neonatal
mouse (bronchopulmonary dysplasia (BPD) mouse model)
is a convenient animal model to simulate injurious events
in a developmental stage of the lung in which usually pre-
term infants are born. According to the current knowledge,
the alveolar myofibroblast is considered to be the cell type
responsible for the secondary septae formation. Further-
more, during alveolar stage, the lung vasculature, which still
consists of a double layer of capillaries, becomes a single ca-
pillary network via a process called microvascular matur-
ation in order to allow more efficient oxygen intake
(Fig. 1d). In contrast to the above-mentioned classification











































Fig. 1 Schematic representation of alveologenesis and cell types involved. a During the saccular stage, the lung forms primitive alveoli (saccule)
surrounded by collagen fibers, nerves, and blood vessels. b The alveolar saccule in the saccular stage is characterized by the presence of AEC I/II,
coating the walls of saccule, surfactant production, expansion of capillary tree, production of collagen, and elastin by fibroblasts. c During the
alveolar stage, the lung undergoes subdividing of sacs by a process called “secondary septation” that will give rise to mature alveoli. d Secondary
septae starts to appear at the place of elastin deposition, which is produced by alveolar MYF. The septae elongates towards the alveolar sac
airspace. Double layer of capillaries become thinner giving rise to a one-layer network for more efficient gas exchange. e AEC I/II alveolar epithelial
cell type I/II, BADJ broncho-alveolar duct junction, LIF lipofibroblast, MYF myofibroblast
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suggested to classify lung development according to two
distinct developmental processes: (1) the branching mor-
phogenesis program (E9.5–E16.5) and (2) the alveolar epi-
thelial differentiation program (E16.5–P30). During the
branching morphogenesis program, the distal epithelial
progenitors give rise to several differentiated epithelial cell
types of the conducting airway [5]. During the alveolar epi-
thelial differentiation program, the epithelial progenitors
give rise to the AEC I/AEC II cells [1].
This review will summarize the current understanding
of lung epithelial and mesenchymal cell lineage forma-
tion during development, while focusing on key cellular
players (Table 1) and the fibroblast growth factor 10
(FGF10) signaling pathway involved in alveologenesis.
We refer to other outstanding reviews for more detailed
information on lung development [6].
Epithelial cell lineage formation and FGF10
signaling
Beginning at the pseudoglandular stage of embryonic lung
development, a complex interaction amongst the following
three morphologically distinguishable compartments of the
lung occurs: mesothelium (most distal/outer layer), mesen-
chyme (middle layer subdivided into submesothelial mesen-
chyme (SMM), and subepithelial mesenchyme (SEM)) and
epithelium (proximal/inner layer). Additionally, the endo-
thelium arises within the mesenchyme from E10 onwards.
Through an elaborate signaling network, these different
compartments interact with each other via a process called
induction to specify the differentiation of the adjacent tissue
in a certain direction [7]. This process controls the prolifer-
ation, amplification, differentiation, and migration of di-
verse epithelial and mesenchymal progenitor cells along the
proximal-distal axis of the lung. In the following section,
the present knowledge on epithelial cell lineage formation
during lung development—with emphasis on the AEC I
and AEC II cells—will be reviewed.
The first multipotent epithelial progenitor cell de-
tected at the distal tip of the embryonic lung at E10.5
expressed SRY (sex determining region Y)-box 9 (Sox9) as
well as the inhibitor of differentiation 2 (Id2). Using a
lineage tracing approach (Id2Cre-ERT2 knock-in mouse
line), Rawlins and colleagues demonstrated that Id2+
progenitor cells labeled at the pseudoglandular stage give
rise to all the epithelial cell types of the lung [8]. By con-
trast, labeling of Id2+ cells during the canalicular stage
captured only the differentiated cells along the alveolar
lineage, the AEC I and II cells. These findings suggest
that Id2 during the pseudoglandular stage is a marker
for the multipotent epithelial progenitor cells, which ini-
tially differentiate into bronchiolar progenitors (Sox2+).
The bronchiolar progenitor cells give rise to club cells,
ciliated cells, goblet cells, and neuroendocrine cells, all
of which populate the conducting airway epithelium.
Interestingly, lineage tracing using the calcitonin gene-
related peptide (Cgrp) promoter to target the neuroendo-
crine cells during lung development showed that Cgrp+
cells labeled at E12.5 can also give rise to AEC I and AEC
II cells in the adult lung [9]. The exact relationship be-
tween Cgrp+ cells (which include mostly the neuroen-
docrine cells) and other lung cell types during normal
development and homeostasis is still under investiga-
tion. As development proceeds, multipotent epithelial
progenitor cells give rise during the canalicular stage
to alveolar/bipotent progenitors (Id2+, Sox9+, Pdpn+,
Sftpc+), which contribute to the AEC I and AEC II
Table 1 Overview of cells relevant for alveologenesis
Name of cell Name of progenitor cell Localization of cell Function of cell for
alveologenesis
Interaction with other cells
Alveolar epithelial cell
type I (AEC I)
Bipotent progenitor
(Sftpc+, Pdpn+) [1]
Epithelium Providing the majority of
alveolar
surface area
AEC II (during regeneration) [16]
Alveolar epithelial cell
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after lung injury [16]







Alveolar myofibroblast Alveolar myofibroblast
progenitor; Pdgfra + LIF
(to be validated) [25]
Mesenchyme, Tip of growing
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Deposition of Elastin in the








Secretion of triglycerides and
leptin for AEC II [37] postnatal
niche for AEC II [34]
AEC II [35, 37], epithelium
(Pdgfa) [31]
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cells. The cellular and molecular mechanisms regulating
these different developmental decisions are still unclear.
In particular, what is controlling the differentiation of the
multipotent progenitors (Id2+, Sox9+) into alveolar/bipo-
tent progenitors (Id2+, Sox9+, Podoplanin+, Sftpc+) is so
far unknown. Chang and colleagues showed that the epi-
thelial overexpression of small GTPase Kras inhibited
differentiation towards the AEC I/AEC II cell lineage
but promoted the branching program [5]. In addition,
it has been demonstrated that ubiquitous expression of
Fgf10 from the beginning of the pseudoglandular stage
prevents the differentiation of multipotent epithelial
progenitor cells into Sox2+ bronchiolar progenitor cells
[10]. Additionally, the ubiquitous expression of Fgf10 at
later time points during the pseudoglandular stage,
which allows the formation of Sox2+ bronchiolar progeni-
tor cells, prevented the differentiation of these bronchiolar
progenitors into ciliated cells, directing them instead
towards the p63+ basal cell lineage [10]. Using the
Ccsp-rtTA;tet(O)Cre mouse line to permanently activate
green fluorescent protein (GFP) reporter expression in
the context of a lineage tracing experiment, it was re-
ported that club cells (secretoglobin, family1A, member
1 (Scgb1a1+)) give rise to club and goblet cells, whereas
neuroendocrine cells remained unlabelled [11].
The role of FGF10 in the formation and
maintenance of the alveolar lineage is still elusive
Interestingly, bipotent (Sftpc+, Pdpn+) progenitor cells,
which give rise to AEC I and AEC II, express high levels
of Etv5, a downstream target of FGF signaling, as well as
the gene encoding the FGF10 receptor, Fgfr2b [1]. Due
to the lung agenesis phenotype displayed by Fgf10 [12]
or Fgfr2b null embryos [13], the role of FGF10/FGFR2b
signaling in the formation of the alveolar lineage has
been suggested mostly from partial loss or gain of func-
tion approaches. Fgf10 is one of the most important de-
velopmental genes expressed in the submesothelial
mesenchyme of the developing lung from the onset of
organogenesis. It encodes a secreted diffusible protein,
which acts in a paracrine fashion mainly through the
epithelial receptor FGFR2b [14] during the pseudogland-
ular stage of lung development (embryonic day E9.5
through E16.5 in mice). FGF10 plays a crucial role in
controlling epithelial morphogenesis, a process forming
a stereotypic set of epithelial tubes organized as a tree
and which are the precursors of the conducting airways.
In vitro experiments suggest that FGF10 acts primarily
on the epithelium by promoting chemotaxis rather than
proliferation [15]. In addition, during the pseudoglandu-
lar stage, FGF10 has been shown to maintain the undif-
ferentiated status of the SOX9+/ID2+ cells in the distal
epithelium [10]. Based on single-cell transcriptomics
studies of the epithelium during lung development, the
alveolar progenitors have been proposed to represent a
progenitor population-baptized “bipotent progenitor cells”
[1]. These bipotent epithelial progenitor cells can differen-
tiate into either AEC I or AEC II cells, but what is control-
ling their differentiation is still unknown. Desai and
colleagues demonstrated that postnatally new AEC I cells
derive from mature AEC II cells produce expanding clonal
foci of alveolar renewal. This stem cell function of the
AEC II is induced by injury of the alveolar epithelium [16].
Interestingly, FGF10 is being secreted by LIFs (see below
mesenchymal cell lineage formation and FGF10 signaling).
LIFs are located in close proximity to AEC II. It is tempt-
ing to speculate that FGF10 secreted by the LIFs is essen-
tial for maintaining the AEC II stem cells, but this remains
to be tested experimentally in mice via the deletion of the
main receptor Fgfr2b in conjunction with lineage tracing
in the mature AEC II cells. A gene signature characteristic
of AEC I and AEC II has been reported. The bipotent
progenitor cells exhibit both signatures. Unpublished
data indicate that FGF10 could play an important role
in directing the differentiation of the bipotent progeni-
tor cells towards the AEC II lineage (Chao C. M. and
Bellusci S., in preparation), and also for the differenti-
ation of the vascular system and the formation of the
alveolar myofibroblasts, a key cell type in the secondary
septae. Consistent with this possibility, we previously
reported that use of an Fgf10 hypomorph allele, which
constitutively reduces Fgf10 expression (to around 20 %
of the normal level observed in WT), leads to impaired
alveolar lineage formation with a significant reduction
of surfactant proteins [17]. During the pseudoglandular
stage, FGF10 also indirectly orchestrates the development
of the adjacent mesenchyme, which contains the progeni-
tors for a number of important lung mesenchymal cell
types, including the endothelium, the vascular and airway
smooth muscle cells, the alveolar myofibroblasts, the
lipofibroblasts, the interstitial fibroblasts, and the nerve
cells [7, 18]. More detailed information about the al-
veolar myofibroblasts and lipofibroblasts will be given
in the next section. Such impact on the mesenchyme is
unsurprising, as FGF10 signaling is embedded in an
interactive signaling network comprising major pathways
such as retinoid acid, Sonic hedgehog, bone morpho-
genetic protein 4, transforming growth factor ß-1, WNT,
platelet-derived growth factor, and vascular endothelial
growth factor. In addition to its developmental role,
FGF10 is a major player in the regeneration of the lung
after injury. Upon bleomycin-mediated lung injury in
mice, fibrosis development is thought to occur primarily
via alveolar epithelial cell damages and pulmonary inflam-
mation. In this model, Fgf10 overexpression demonstrated
a protective and therapeutic effect by increasing fibrosis
resolution. The proposed mechanism is FGF10-mediated
AEC II survival. FGF10 is also involved in the regeneration
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of the bronchial lung epithelium after naphthalene in-
jury [19, 20].
Mesenchymal cell lineage formation and FGF10
signaling
Lung mesenchymal cells such as smooth muscle cells
(SMCs), endothelial cells, nerve cells, lipofibroblasts, al-
veolar myofibroblasts, lymphatic cells, and others play a
very important role in lung development and homeosta-
sis. During the alveolar stage of lung development, two
mesenchymal lineages are prevalent: the alveolar myofi-
broblasts (MYF) and the lipofibroblasts (LIF).
Alveolar myofibroblasts (MYF) are believed to
play a key role in the process of alveologenesis
Alveolar MYF are present in the lung during the postna-
tal alveolar stage, being located at the tip of forming the
secondary septae. They form elongated cytoplasmic pro-
trusions to establish a continuous loop around the nas-
cent septal cup. These loops are interconnected, giving
rise to a “fishnet”-like α-smooth muscle actin network,
with strings of the fishnet underlying future alveolar
ridges [21]. Alveolar MYF are defined by expression of
alpha-smooth muscle actin (a-SMA or Acta2) and pro-
duction of extracellular matrix fibers, such as elastin and
collagen. Deposition of elastin, which allows the alveoli
to stretch during the inhalation process, is an essential
process for septation [22]. After birth, elastin forms a
matrix, serving as a scaffold on which alveolar MYF ad-
heres and marking sites of the secondary septae. Elastin-
knock-out mice failed to form the secondary septae,
which led to an emphysematous-like phenotype and the
mutant mice dying within a few days after birth, prior to
the onset of alveologenesis [23].
It is believed that alveolar MYF are derived from Pdgf
receptor alpha (Pdgfra)-positive cells. During alveologen-
esis, PDGFRa-positive cells are present at the tips of the
forming secondary septae. In Pdgfa-null mice (PDGFa is
the ligand of PDGFRa), PDGFRa-positive cells are no
longer present in the lung and this is associated with an
impaired secondary septae formation [24]. The origin of
the alveolar myofibroblasts is still controversial. How-
ever, it appears that FGFR2b ligands are critical for their
formation. Indeed, Fgf10 hypomorphic lungs display en-
larged respiratory airways at birth characterized by the
absence of smooth muscle actin-positive myofibroblasts
[17]. Furthermore, inhibition of all FGFR2b ligands using
a dominant negative approach with expression of a soluble
form of FGFR2b (Spc-rtTA/+; tet(O)solFgfr2b/+) from
E14.5 to E18.5 disrupts alveologenesis. In this context, de-
fective secondary septae formation can be corrected by ret-
inoic acid administration. However, re-expression of the
dominant negative sFgfr2b to inhibit FGFR2b ligands blocks
the retinoic acid-induced regeneration process, indicating
that FGFR2b ligands expressed in the postnatal lung
are also critical for the formation of the secondary sep-
tae [25]. Additionally, it was shown that in a model of
re-alveolarization after pneumonectomy, FGFR2b ligands
are required for alveolar MYF formation during regener-
ation [26]. This study also proposed that alveolar MYF
arise from Pdgfra-positive LIF and that FGFR2b ligands
(likely FGF10) are (is) involved in the differentiation of
Pdgfra-positive cells into alveolar MYF. Altogether, these
data indicate that one or several FGFR2b ligands, in par-
ticular FGF10, are/is directly responsible for the formation
of the alveolar myofibroblasts. However, it is still unclear if
this results from a direct effect of FGF10 on the alveolar
myofibroblast progenitors or if this effect is indirect via
the action of FGF10 on the AEC II cells, which are also a
major component of the forming alveoli. The use of spe-
cific driver lines to target the alveolar myofibroblast pro-
genitors will be instrumental to follow their fate in the
context of lung injury or regeneration. Interestingly, in-
creased levels of FGF signaling in the lung mesenchyme
during development leads to absence of alveolar MYF at
birth and reduced elastin deposition [27]. FGF signaling is
therefore also capable of repressing the differentiation of
the alveolar MYF progenitors. It is possible that different
FGF ligands, acting via either the c- or the b-isoform of
FGF receptors, either prevent the differentiation of the al-
veolar MYF progenitors allowing their proliferation or
trigger their differentiation. Further investigation will be
required to test this possibility. Recently, Branchfield and
colleagues suggested that Pdgfra-positive cells differentiate
into MYF during alveologenesis and later adopt a lipofi-
broblast fate [21]. However, as these experiments were not
based on lineage tracing approaches, these conclusions are
still debatable. It has also been suggested from in vitro
studies that sonic hedgehog (SHH) signaling drives migra-
tion of lung alveolar myofibroblasts towards the sites of
secondary septation [28]. Gli1 is known to be a down-
stream target of SHH signaling. By using a Gli1-CreERT2
mouse line, which targets cells that are responding to
SHH signaling, Li and colleagues demonstrated that
Gli1+ cells labeled during early embryonic development
(E10.5–E11.5) served as progenitors for alveolar MYF.
This process also depended on WNT signaling [29].
Lipofibroblast is a subset of fibroblasts
characterized by the presence of lipid droplets
These cells are abundant in the late stages of lung devel-
opment and postnatally and are located in close proxim-
ity to AEC II [30]. LIF serve as a source of lipids, which
are transported to AEC II for surfactant production [31].
Recently, it was shown that Fgf10-expressing cells give rise
to a subset of the LIF lineage during development [32].
Additionally, in postnatal lungs, a significant proportion of
LIF express Fgf10 and FGF10 appears to contribute to
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their formation [33]. We hypothesize that FGF10 secreted
by the LIFs is essential for maintaining the AEC II stem
cells, but this remains to be tested. It was shown that
Pdgfra+ cells/LIF constitute a stem cell niche for AEC II
stem cells [34]. LIF and AEC II co-cultured in Matrigel
form alveolosphere-like structures. It has been proposed
that AEC II signal to LIF via parathyroid hormone-related
protein (PTHRP), which then activates the peroxisome
proliferator-activated receptor gamma (PPARg) pathway.
Activation of the PPARg pathway leads to expression of
adipose differentiation-related protein (Adrp or perilipin
2, Plin2) by LIF. ADRP is necessary for lipid trafficking
and regulation of surfactant production. In addition to tri-
glycerides, LIF also secretes leptin and retinoic acid, both
of which are necessary for surfactant production and al-
veolar septation [35–37].
During the early pseudoglandular stage (E10.0), the
lung vasculature starts to form by processes called
angiogenesis and vasculogenesis. During angiogenesis,
the capillaries form by sprouting from pre-existing endo-
thelial cells, whereas vasculogenesis is characterized by
migration and differentiation of endothelial progenitor
cells (or hemangioblasts) in the distal mesenchyme to
form new blood vessels. Several studies have confirmed
that endothelial progenitors are located in the SEM and
expressed vascular endothelial growth factor receptor 2
(Vegfr2 or Flk-1) as an early marker [38]. However, the
origin of the endothelial progenitors is still not clear.
Most of the endothelial progenitors seem to arise from
Wnt2+, Gli1+, and Isl1+ cells (coming from the second
heart field) [39] as well as Pdgfrb+ cells [40] and meso-
thelial cells [41]. Recently, our group demonstrated that
Fgf10+ cells give rise to a subset of progenitors for the
vascular smooth muscle cells [32]. Increasing evidence
gained from in vitro recombination studies (co-culture
of epithelium and mesenchyme and mesenchyme alone)
as well as in vivo animal models showed that endothelial-
epithelial tissue interaction is essential for branching mor-
phogenesis as well as alveologenesis. However, this is still
controversial as it has recently been shown in vitro that
the endothelial cells are not required for the branching of
the lung epithelium. In E12.5 lung explants, the lung epi-
thelium was able to branch despite blockade of vascular
endothelial growth factor (VEGF) signaling with three dif-
ferent VEGF receptor inhibitors (SU5416, Ki8751, and
KRN633) [42]. On the other side, supporting a role of the
endothelium in the branching of the lung epithelium,
Lazarus and colleagues demonstrated that the epithelial
branching process was interrupted upon an in vivo in-
ducible decoy VEGFR1 receptor expression (to block
VEGFR1 ligands such as VEGFa) [43]. The authors also
found that Spry2 is upregulated in the epithelium upon
inhibition of VEGFR1-mediated signaling, suggesting
an inhibition of FGF signaling (SPRY2 is an inhibitor of
FGF10) which is essential for branching morphogenesis
[43]. Consistent with this, FGF10 leads to the upregula-
tion of Vegf in the distal epithelium [44]. We previously
published that embryonic lung explants treated with re-
combinant VEGFa led to upregulation of Vegfr2 in the
mesenchyme and branching of the epithelium [45].
Whether this effect of VEGFa on epithelial branching is
direct or indirect needs to be investigated. Additional
strong evidence came from the platelet endothelial cell
adhesion molecule (Pecam1)-deficient mice that failed
to form endothelial cells and displayed alveolar simpli-
fication [46]. Consistent with the findings that VEGFa
is downregulated in preterm infants with BPD, Thebaud
and colleagues showed in a rat model of BPD that
adenoviral administration of VEGF improved alveolar
architecture [47]. However, the use of VEGF alone as a
treatment may be limited as capillary leakage is also ob-
served upon VEGF treatment [47]. Another confirm-
ation for the link between the lung vasculature and
alveologenesis has been demonstrated convincingly by
induced endothelium-specific deletion of Vegfr2 and
Fgfr1 in a pneumonectomy mouse model leading to im-
paired compensatory lung growth [48]. Based on these
data, the current consensus is that vascular growth is a
driving force for alveologenesis.
FGF10 in human lung diseases
Heterozygous mutations in the human FGF10 or FGFR2B
gene result in aplasia of lacrimal and salivary glands (ALSG)
and lacrimo-auriculo-dento-digital syndrome (LADD),
respectively [49, 50]. While babies with ALSG or LADD
do not display apparent lung defects, adult patients
with heterozygous loss of function of FGF10 exhibit a
significant decrease in inspiratory vital capacity (IVC),
forced expiratory volume in one second (FEV1), and
FEV1/IVC quota compared to non-carrier siblings and
predicted reference values [51]. These data are consist-
ent with chronic obstructive pulmonary disease. Based
on our recent data gained from Fgf10 heterozygous
(Fgf10+/−) mice (Chao C. M. and Bellusci S., data not
published), we hypothesize that these patients acquired
a lung phenotype which might be due to quantitative
and qualitative congenital defects of the AEC I and
AEC II cells emerging during alveolar cell lineage for-
mation and leading postnatally to abnormal epithelial
repair processes after injury. In humans, exposure to
inflammation is known to increase the risk for develop-
ing BPD [52]. Consistent with this fact, it has been
demonstrated that interactions between nuclear factor
“kappa-light-chain-enhancer” of activated B cells (NF-κB),
specificity protein 1 (SP1), and SP3 led to inhibition of
Fgf10 expression [53]. Fgf10 inhibition is mediated by Toll-
like receptor 2 and 4 (TLR2 or TLR4) activation, and de-
creased FGF10 concentration was found in lung samples
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from children suffering from BPD [54]. These data pro-
vided clues to molecular mechanisms linking inflammatory
signaling to this important developmental gene, which
might play a role in BPD pathogenesis.
Summary
In view of the numerous lung diseases characterized by
a lack and/or destruction of alveoli (e.g., BPD, chronic
obstructive pulmonary disease (COPD)), the fundamen-
tal understanding of the alveologenesis process with its
coordinated cellular interactions and intricate signaling
network occurring between epithelial, mesenchymal, and
endothelial is essential. For this purpose, developmental
biologists have been working extensively to unravel the
molecular and cellular bases of mouse lung development,
both pre- and postnatally. In the future, the pneumonec-
tomy mouse model combined with genetically modified
mouse lines, lineage tracing approaches, and single-cell
transcriptomic analyses will be powerful tools to shed new
lights on the regenerative aspects associated with de novo
alveologenesis. Such knowledge is critical to develop in-
novative therapies to treat lung diseases.
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